GeneDx Holdings (WGS) Receivables - Net (2020 - 2025)
GeneDx Holdings (WGS) has disclosed Receivables - Net for 6 consecutive years, with $74.4 million as the latest value for Q4 2025.
- On a quarterly basis, Receivables - Net rose 97.64% to $74.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $74.4 million, a 97.64% increase, with the full-year FY2025 number at $74.4 million, up 97.64% from a year prior.
- Receivables - Net was $74.4 million for Q4 2025 at GeneDx Holdings, up from $60.9 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $74.4 million in Q4 2025 to a low of $498000.0 in Q3 2023.
- A 5-year average of $35.2 million and a median of $35.5 million in 2021 define the central range for Receivables - Net.
- Peak YoY movement for Receivables - Net: crashed 98.83% in 2023, then soared 7574.7% in 2024.
- GeneDx Holdings' Receivables - Net stood at $26.5 million in 2021, then skyrocketed by 60.83% to $42.6 million in 2022, then decreased by 24.07% to $32.4 million in 2023, then grew by 16.24% to $37.6 million in 2024, then surged by 97.64% to $74.4 million in 2025.
- Per Business Quant, the three most recent readings for WGS's Receivables - Net are $74.4 million (Q4 2025), $60.9 million (Q3 2025), and $48.0 million (Q2 2025).